Literature DB >> 20205101

The prevalence of benign and malignant neoplasms in acromegalic patients.

Agata Bałdys-Waligórska1, Anna Krzentowska, Filip Gołkowski, Grzegorz Sokołowski, Alicja Hubalewska-Dydejczyk.   

Abstract

INTRODUCTION: In acromegalic patients, the prevalence of certain benign and malignant neoplasms is higher than that in the healthy population. We retrospectively evaluated the prevalence of tumours in acromegalic patients treated at our department: the regional centre for acromegalic patients for the Małopolskie voivodeship in Poland.
MATERIAL AND METHODS: During the years 1983-2008, a hundred and one acromegalic patients (30 males and 71 women), of mean age 51.8 +/- 15.4 years, were diagnosed and treated. Pituitary macroadenoma and microadenoma were stated in 63.4% and 25.7% of these patients, respectively. In 10.9% of these patients no data on tumour diameter were available. The mean observation period was 9.4 +/- 6.5 years. The median levels of hGH and IGF-1 prior to neurosurgery were 20.2 (IQR = 34.9) ng/ml and 764.5 (IQR = 569.6) ng/ml, respectively.
RESULTS: In the studied group of patients, we found the following prevalence of various tumours: nodular goitre - 64/101 patients (63.0%), polyps of the colon - 13/101 patients (13.0%); uterine polyps - 4/101 patients (4.0%); and prostate adenoma - 2/101 patients (2.0%). Among malignant tumours, thyroid cancer, endometrium and cervix cancer were the most frequent, each of these occurring in 3 patients (3.0%). Colon cancer prevalence was 2.0% (in 2 patients).
CONCLUSIONS: From our retrospective study, we suggest an overall increase of tumour incidence in acromegalic patients. Prospective multicentre studies are required to resolve the significance of this observation. In our study group, the number of malignant neoplasms was significantly higher in patients with long-lasting uncontrolled disease (over 5 years), compared to patients with controlled disease. (Pol J Endocrinol 2010; 61 (1): 29-34).

Entities:  

Mesh:

Year:  2010        PMID: 20205101

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  13 in total

1.  Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.

Authors:  Erica Gentilin; Mariella Minoia; Marta Bondanelli; Federico Tagliati; Ettore C Degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2016-09-01       Impact factor: 3.633

2.  Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients.

Authors:  Serkan Dogan; Aysegul Atmaca; Selcuk Dagdelen; Belkis Erbas; Tomris Erbas
Journal:  Endocrine       Date:  2013-05-14       Impact factor: 3.633

3.  The prevalence of secondary neoplasms in acromegalic patients: possible preventive and/or protective role of metformin.

Authors:  Denise Costa; Filippo Ceccato; Rosa Lauretta; Valeria Mercuri; Tania D'Amico; Corrado De Vito; Carla Scaroni; Marialuisa Appetecchia; Patrizia Gargiulo
Journal:  Int J Clin Oncol       Date:  2021-03-13       Impact factor: 3.402

4.  Pulmonary epidermoid carcinoma in a patient with acromegaly: a rare entity.

Authors:  Siham El Aziz; Asma Chadli; Atika Obbiba; Hassan El Ghomari; Ahmed Farouqi
Journal:  Pan Afr Med J       Date:  2012-06-10

Review 5.  Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review.

Authors:  Kosma Wolinski; Agata Czarnywojtek; Marek Ruchala
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

6.  Increased prevalence of colorectal polyp in acromegaly patients: a case-control study.

Authors:  Ali Riza Koksal; Meltem Ergun; Salih Boga; Huseyin Alkim; Mehmet Bayram; Yuksel Altuntas; Banu Ozguven Yilmaz; Canan Alkim
Journal:  Diagn Ther Endosc       Date:  2014-12-29

7.  Achalasia and acromegaly: Co-incidence of these diseases or a new syndrome?

Authors:  Jiri Dolina; Lumir Kunovsky; Radek Kroupa; Karel Stary; Petr Jabandziev; Tereza Nesporova; Karel Maca; Tomas Andrasina; Filip Marek; Zdenek Kala; Jitka Vaculova; David Said; Martina Zapletalova; Jan Lochman; Hana Palova Noskova; Ondrej Slaby; Lydie Izakovicova Holla; Petra Borilova Linhartova
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2021-07-02       Impact factor: 1.245

8.  Risk of neoplasms in acromegaly.

Authors:  Marek Ruchała; Ewelina Szczepanek-Parulska; Maciej Fularz; Kosma Woliński
Journal:  Contemp Oncol (Pozn)       Date:  2012-05-29

9.  AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up.

Authors:  Caterina Mian; Filippo Ceccato; Susi Barollo; Sara Watutantrige-Fernando; Nora Albiger; Daniela Regazzo; Paola de Lazzari; Gianmaria Pennelli; Sandra Rotondi; Davide Nacamulli; Maria Rosa Pelizzo; Marie-Lise Jaffrain-Rea; Franco Grimaldi; Gianluca Occhi; Carla Scaroni
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

10.  Insulin-like growth factor-i and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition.

Authors:  Julie A Schmidt; Naomi E Allen; Martin Almquist; Silvia Franceschi; Sabina Rinaldi; Sarah J Tipper; Konstantinos K Tsilidis; Elisabete Weiderpass; Kim Overvad; Anne Tjønneland; Marie-Christine Boutron-Ruault; Laure Dossus; Sylvie Mesrine; Rudolf Kaaks; Annekatrin Lukanova; Heiner Boeing; Pagona Lagiou; Dimitrios Trichopoulos; Antonia Trichopoulou; Domenico Palli; Vittorio Krogh; Salvatore Panico; Rosario Tumino; Roberto Zanetti; H Bas Bueno-de-Mesquita; Petra H Peeters; Eiliv Lund; Virginia Menéndez; Antonio Agudo; María-José Sánchez; Maria-Dolores Chirlaque; Eva Ardanaz; Nerea Larrañaga; Joakim Hennings; Maria Sandström; Kay-Tee Khaw; Nick Wareham; Isabelle Romieu; Marc J Gunter; Elio Riboli; Timothy J Key; Ruth C Travis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-19       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.